Achema middle east

Drug Research

PCI Pharma Services Announces Major Investment to Expand Development and Manufacturing Capabilities at Tredegar, UK Site

PCI Pharma Services (PCI), a leading pharmaceutical and biopharmaceutical global outsourcing solutions provider, announced it has begun an expansion of its Tredegar facility in Wales, UK to enhance its high potent drug manufacturing and development capabilities, including both clinical...

Spotlight on Abzena’s Developability Platform during Antibody Engineering & Therapeutics 2019

Abzena is showcasing its new Developability Service, enabling biotechnology and pharmaceutical companies to improve lead selection and de-risk cell line development, at Antibody Engineering & Therapeutics 2019 being held 9–13 December, on Booth #414 at the Marriott Marquis San...

Big pharma agrees to drastically cut prices of blockbuster drugs in China

China’s National Healthcare Security Administration (NHSA) has announced it has agreed an average 61% cut in prices of 70 top-selling drugs with large pharma manufacturers in exchange for inclusion on a state-run insurance scheme list. According to the South China...

FDA approves Aleors Diclofenac sodium topical solution

The US Food and Drug Administration (FDA) has granted tentative approval for Aleor Dermaceuticals’ Diclofenac sodium topical solution USP, 2% w / w to treat the pain of osteoarthritis of the knees. Aleor is a 60:40 joint venture (JV) between...

Aptar Pharma, Platinum Sponsor at DDL 2019, to Showcase Expanded Portfolio of Respiratory Innovations and Services

Aptar Pharma, a leading drug delivery systems provider, announces its Platinum Sponsorship of this year’s Drug Delivery to the Lung (DDL) Conference 2019, which takes place from December 11-13 in Edinburgh, Scotland. DDL provides an annual forum for scientists, academics,...

Chi-Med Announces Surufatinib Granted FDA Orphan Drug Designation for Pancreatic Neuroendocrine Tumors

Hutchison China MediTech Limited announces that the U.S. FDA has granted Orphan Drug designation to surufatinib for the treatment of pancreatic neuroendocrine tumors. “NET is an area of significant unmet medical need. The current treatment options are very limited,” said...

Bayer and Dewpoint Therapeutics partner to research new treatments for cardiovascular and gynecological diseases

Bayer and Dewpoint Therapeutics, a biotechnology company with sites in Boston and Dresden, Germany, announced an option, research and license agreement worth up to USD 100 million. The partnership will leverage Dewpoint’s proprietary platform for biomolecular condensates and Bayer’s...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »